Drug firm Lupin on Thursday said it has received an approval from the U.S. health regulator to market a generic non-steroidal anti-inflammatory drug in the American market.
The company has received an approval from the U.S. Food and Drug Administration for Diclofenac Sodium Topical Solution, Lupin said in a statement.
The company's product is a generic equivalent of Horizon Pharma's Pennsaid Topical Solution, it added.
The product will be manufactured at Lupin's facility in Pithampur, Madhya Pradesh.
ADVERTISEMENT
As per IQVIA MAT June 2022 data, Diclofenac Sodium Topical Solution had estimated annual sales of $484 million in the U.S.
Shares of Lupin on Thursday ended 0.23% up at Rs 662.70 apiece on the BSE.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
POPULAR
1
Mumbai Rains LIVE: Mumbai Now On Yellow Alert Till 7 P.M.
2
Stocks Join Bonds Higher At Start Of Big Fed Week: Markets Wrap
3
Oil Advances As Ukraine Steps Up Attacks On Russian Supplies
4
UCO Bank Gets Approval To Work With Sanctioned Refiner Nayara Energy
5